Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230019/S002

MediBeacon Transdermal GFR Measurement System (TGFR)

Medibeacon, Inc. · Decision date Jun 10, 2026

FDA DECISIONP230019/S002

What did the FDA approve?

FDA records P230019/S002 as a supplement to PMA P230019, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jun 10, 2026.

FDA approval order statement

approval for the following labeling revision: (Prior warning statement) Lumitrace injection may interfere with clinical laboratory tests. The presence of Lumitrace decreased B-Type Natriuretic Peptide (BNP) results by around 20% in limited testing. DO NOT ADMINISTER if the patient is expected to need clinical laboratory testing while Lumitrace is present in their system (up to 72 hours for renally impaired patients).(Revised warning statement) Lumitrace injection may interfere with clinical laboratory tests. DO NOT ADMINISTER if the patient is expected to need clinical laboratory testing while Lumitrace is present in their system, which may be for up to 72 hours.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Gastroenterology, Urology
Decision date
Jun 10, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P230019/S002
Regulatory pathway
PMA supplement
Product code
SDK
Decision code
APPR
Decision date
Jun 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transdermal test for Assessment of Glomerular Filtration Rate.

Product code
SDK
FDA device class
3

For the original device and its historical approval scope, see PMA P230019. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230019 · Original PMA

    MediBeacon Transdermal GFR Measurement System (TGFR)

  2. P230019/S002 received

    Application receipt date recorded by FDA.

  3. P230019/S003 · Related supplement

    MediBeacon Transdermal GFR Measurement System (GFR)

  4. P230019/S001 · Related supplement

    MediBeacon Transdermal GFR Measurement System (TGFR)

  5. P230019/S002 · FDA decision

    Real-Time Process

  6. P230019/S005 · Related supplement

    MediBeacon Transdermal GFR System

Timeline entries are records held by MedtechLedger for P230019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230019

Product / regulatory recordCompanyPathwayDecision dateSource
Medibeacon, Inc.PMA approvalJan 17, 2025FDA
Medibeacon, Inc.PMA supplementNov 20, 2025FDA
Medibeacon, Inc.PMA supplementDec 15, 2025FDA
Medibeacon, Inc.PMA supplementOct 2, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medibeacon, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
425 N. New Ballas Rd., Suite 100, St. Louis, MO, 63141

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records